These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 35078637)

  • 1. Newer oral antivirals for COVID-19: Are they the real game changer?
    Kunal S; Sakthivel P; Malhotra N; Ish P
    Heart Lung; 2022; 52():200-203. PubMed ID: 35078637
    [No Abstract]   [Full Text] [Related]  

  • 2. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
    Abdelnabi R; Foo CS; Kaptein SJF; Zhang X; Do TND; Langendries L; Vangeel L; Breuer J; Pang J; Williams R; Vergote V; Heylen E; Leyssen P; Dallmeier K; Coelmont L; Chatterjee AK; Mols R; Augustijns P; De Jonghe S; Jochmans D; Weynand B; Neyts J
    EBioMedicine; 2021 Oct; 72():103595. PubMed ID: 34571361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance.
    Flisiak R; Zarębska-Michaluk D; Rogalska M; Kryńska JA; Kowalska J; Dutkiewicz E; Dobrowolska K; Jaroszewicz J; Moniuszko-Malinowska A; Rorat M; Podlasin R; Tronina O; Rzymski P
    Pharmacol Rep; 2022 Dec; 74(6):1279-1285. PubMed ID: 36001284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly sensitive high-performance thin-layer chromatography method for the simultaneous determination of molnupiravir, favipiravir, and ritonavir in pure forms and pharmaceutical formulations.
    Saraya RE; Deeb SE; Salman BI; Ibrahim AE
    J Sep Sci; 2022 Jul; 45(14):2582-2590. PubMed ID: 35583051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral antiviral treatments for COVID-19: opportunities and challenges.
    Rahmah L; Abarikwu SO; Arero AG; Essouma M; Jibril AT; Fal A; Flisiak R; Makuku R; Marquez L; Mohamed K; Ndow L; Zarębska-Michaluk D; Rezaei N; Rzymski P
    Pharmacol Rep; 2022 Dec; 74(6):1255-1278. PubMed ID: 35871712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19.
    Kulkarni P; Padmanabhan S
    Biotechnol Lett; 2022 Jul; 44(7):831-843. PubMed ID: 35608787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
    McMahon JH; Lau JSY; Roney J; Rogers BA; Trubiano J; Sasadeusz J; Molton JS; Gardiner B; Lee SJ; Hoy JF; Cheng A; Peleg AY
    Trials; 2020 Oct; 21(1):847. PubMed ID: 33050947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comment on: Favipiravir, an antiviral for COVID-19?
    Chachaima-Mar J; Pérez-Castilla J
    J Antimicrob Chemother; 2021 Jan; 76(1):279-280. PubMed ID: 32888000
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
    Eloy P; Le Grand R; Malvy D; Guedj J
    EBioMedicine; 2021 Dec; 74():103663. PubMed ID: 34768087
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.
    Fu D; Cao R; Zhao L; Li W; Zhong W; Wen J
    Crit Care; 2020 Sep; 24(1):578. PubMed ID: 32977854
    [No Abstract]   [Full Text] [Related]  

  • 11. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
    McCullough PA
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32967849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favipiravir as an Antiviral Agent in Coronavirus Disease 2019 (COVID-19): Same Script, Different Cast?
    Dauby N
    Clin Infect Dis; 2021 Aug; 73(3):e847-e848. PubMed ID: 33075124
    [No Abstract]   [Full Text] [Related]  

  • 13. Favipiravir Induced Nephrotoxicity in Two Patients of COVID-19.
    Nasa P; Shrivastava P; Kulkarni A; Vijayan L; Singh A
    J Assoc Physicians India; 2021 Jan; 69(1):90. PubMed ID: 34227789
    [No Abstract]   [Full Text] [Related]  

  • 14. Favipiravir, an antiviral for COVID-19?
    Coomes EA; Haghbayan H
    J Antimicrob Chemother; 2020 Jul; 75(7):2013-2014. PubMed ID: 32417899
    [No Abstract]   [Full Text] [Related]  

  • 15. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
    Waters MD; Warren S; Hughes C; Lewis P; Zhang F
    Environ Mol Mutagen; 2022 Jan; 63(1):37-63. PubMed ID: 35023215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favipiravir Induced Nephrotoxicity in two Patients of COVID-19.
    Nasa P; Shrivastava PK; Kulkarni A; Vijayan L; Singh A
    J Assoc Physicians India; 2021 Jun; 69(6):11-12. PubMed ID: 34472793
    [No Abstract]   [Full Text] [Related]  

  • 17. Favipiravir use for SARS CoV-2 infection.
    Boretti A
    Pharmacol Rep; 2020 Dec; 72(6):1542-1552. PubMed ID: 33108587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pandemic COVID-19, an update of current status and new therapeutic strategies.
    Vitiello A; La Porta R; Trama U; Ferrara F; Zovi A; Auti AM; Di Domenico M; Boccellino M
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Oct; 395(10):1159-1165. PubMed ID: 35779085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An unusual case of bluish discoloration of the cornea after favipiravir therapy for COVID-19.
    Raiturcar TP; Nayak CA
    Indian J Ophthalmol; 2021 Dec; 69(12):3778-3779. PubMed ID: 34827050
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019.
    Koshi E; Saito S; Okazaki M; Toyama Y; Ishimoto T; Kosugi T; Hiraiwa H; Jingushi N; Yamamoto T; Ozaki M; Goto Y; Numaguchi A; Miyagawa Y; Kato I; Tetsuka N; Yagi T; Maruyama S
    CEN Case Rep; 2021 Feb; 10(1):126-131. PubMed ID: 32940880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.